STRIDER Consortium Sites
STRIDER NZAus and STRIDER UK has completed recruitment and the results for the STRIDER UK trials have been published! The Dutch Strider has been stopped following DSMB Recommendation.
Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, Baker PN, Johnstone ED, Khalil A, von Dadelszen P, Papageorghiou AT. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. The Lancet Child & Adolescent Health. 2017 Dec 7.
STRIDER randomised controlled trial is designed to determine whether maternal treatment with oral sildenafil citrate improves perinatal outcomes in pregnancies complicated by severe early-onset IUGR without increasing risks to the mother.
The UBC group is co-ordinating an international consortium of independently funded STRIDER trials with an a priori planned individual participant data (IPD) meta-analysis at the conclusion of these trials. Currently, these trials have been funded in New Zealand and Australia, United Kingdom, the Netherlands and Canada. Each national trial will be performed using a shared protocol.
The primary outcome is post-randomisation abdominal circumference (by ultrasound) growth velocity (STRIDER NZAus), prolongation of pregnancy for one week as a surrogate for long-term morbidity (STRIDER UK), intact perinatal survival until term age (Dutch STRIDER), and gestation age at delivery (STRIDER Canada). After the trials have been completed, the IPD meta-analysis will have sufficient power for a hard perinatal survival outcome.